Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Cue Biopharma Inc (CUE)

Cue Biopharma Inc (CUE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 18,309
  • Shares Outstanding, K 97,283
  • Annual Sales, $ 27,470 K
  • Annual Income, $ -26,600 K
  • EBIT $ -27 M
  • EBITDA $ -26 M
  • 60-Month Beta 1.57
  • Price/Sales 0.63
  • Price/Cash Flow N/A
  • Price/Book 0.54
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.32
  • Most Recent Earnings $0.01 on 03/16/26
  • Next Earnings Date 05/11/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 317.05% (-153.42%)
  • Historical Volatility 140.46%
  • IV Percentile 50%
  • IV Rank 28.42%
  • IV High 1,001.63% on 04/06/26
  • IV Low 45.25% on 11/20/25
  • Expected Move (DTE 9) 0.3230 (117.97%)
  • Put/Call Vol Ratio 0.24
  • Today's Volume 157
  • Volume Avg (30-Day) 20
  • Put/Call OI Ratio 0.14
  • Today's Open Interest 1,269
  • Open Int (30-Day) 1,167
  • Expected Range 0.0000 to 0.5968

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year $-0.17
  • Growth Rate Est. (year over year) +587,747.06%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.1657 +65.24%
on 04/06/26
0.3480 -21.32%
on 03/12/26
-0.0260 (-8.67%)
since 03/06/26
3-Month
0.1657 +65.24%
on 04/06/26
0.4595 -40.41%
on 01/22/26
-0.1191 (-30.31%)
since 01/08/26
52-Week
0.1657 +65.24%
on 04/06/26
1.0300 -73.42%
on 07/16/25
-0.3440 (-55.68%)
since 04/08/25

Most Recent Stories

More News
Cue Biopharma to Receive $7.5 Million Preclinical Milestone Payment from Boehringer Ingelheim Collaboration and License Agreement

Preclinical milestone for selection and approval of first compound for lead optimization has been achieved Further development validates the potential intended mechanistic effect of CUE-501 for T cell-mediated...

CUE : 0.2738 (+45.48%)
Cue Biopharma Announces CEO Transition

BOSTON, March 27, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc.  (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and...

CUE : 0.2738 (+45.48%)
Cue Biopharma to Host Virtual R&D Day Event on April 7, 2026

Virtual Event will feature Key Opinion Leaders (KOLs)  Richard DiPaolo, PhD, and Jonathan Kay, MD, FACP, MACR Cue Biopharma management and KOLs will discuss CUE-401, the company’s lead asset...

CUE : 0.2738 (+45.48%)
Cue Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

Advanced research and development of CUE-401 for IND (Investigational New Drug) readiness – CUE-401 is the Company’s lead asset for the treatment of autoimmune and inflammatory diseases Appointed...

CUE : 0.2738 (+45.48%)
Cue Biopharma to Present New In vitro Data for CUE-401 at the 20th World Immune Regulation Meeting (WIRM) 2026

BOSTON, March 09, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc.  (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and...

CUE : 0.2738 (+45.48%)
Cue Biopharma Announces Preclinical Safety and Tolerability Data for CUE-401 for the Treatment of Autoimmune and Inflammatory Diseases

In two non-GLP studies, CUE-401 was well tolerated with no adverse events observed Proof-of-concept studies reinforce promising preclinical profile and therapeutic potential of CUE-401 BOSTON,...

CUE : 0.2738 (+45.48%)
Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Financial and Business Officer

BOSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc.  (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and...

CUE : 0.2738 (+45.48%)
Cue Biopharma Announces Pricing of $10 Million Public Offering

BOSTON, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate...

CUE : 0.2738 (+45.48%)
Cue Biopharma Announces Proposed Public Offering

BOSTON, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and...

CUE : 0.2738 (+45.48%)
Cue Biopharma Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Announced strategic collaboration and license agreement with ImmunoScape to develop breakthrough cell therapy approach for solid tumors – Company is entitled to receive upfront payments totaling $15M...

CUE : 0.2738 (+45.48%)

Business Summary

Cue Biopharma, Inc. is an immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancers and autoimmune disorders. Cue Biopharma, Inc. is headquartered in Cambridge, Massachusetts.

See More

Key Turning Points

3rd Resistance Point 0.4090
2nd Resistance Point 0.3445
1st Resistance Point 0.3091
Last Price 0.2738
1st Support Level 0.2092
2nd Support Level 0.1447
3rd Support Level 0.1093

See More

52-Week High 1.0300
Fibonacci 61.8% 0.6998
Fibonacci 50% 0.5978
Fibonacci 38.2% 0.4959
Last Price 0.2738
52-Week Low 0.1657

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.